Login to Your Account

Orphazyme ApS Snags $19.7M In Series A for Hsp70 Program

By Marie Powers

Thursday, September 8, 2011
Danish biopharmaceutical company Orphazyme ApS raised €14 million (US$19.7 million) in a Series A financing to move its lead program, Orph-001, into the clinic. The company, based in Copenhagen, is pursuing technology related to molecular chaperone heat-shock protein 70 (Hsp70) to treat disorders known as lysosomal storage diseases (LSD) – a family of more than 45 often-fatal genetic disorders with few existing treatment options.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription